petunia1
3年前
Telo Genomics Appoints Dr. McGlennen as Board Director, a Leader in Commercializing Novel Diagnostic Technologies
Toronto, Ontario--(Newsfile Corp. - February 3, 2022) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that Dr. Ron McGlennen, President and Founder of the medical laboratory Access Genetics, Minnesota, USA, has joined its Board of Directors. Dr. McGlennen brings unique and valuable expertise to TELO's board with extensive experience in successfully introducing novel diagnostics technologies into clinical laboratories across the USA.
Dr. McGlennen brings over 30 years of leadership in the development and commercialization of innovative diagnostic and prognostic technologies across multiple disease areas. He is internationally recognized as an expert in molecular biology and genetics. Over the past decades, Dr. McGlennen has acted as medical director of several clinical laboratories across the USA. He is currently Associate Professor of Pathology at the University of Minnesota Medical School and has published more than 70 peer reviewed publications and book chapters. He holds 9 issued and pending patents. He is board certified in Anatomic and Clinical Pathology and also by the American Board of Medical Genetics, with a specialty in clinical molecular genetics. Dr. McGlennen has also served on a series of governmental and regulatory committees focused on the growth of the field of molecular diagnostics.
"I have previously collaborated with Ron on diagnostics iniatives, and am thrilled that he is now joining the TELO Board of Directors," said Guido Baechler, TELO Chairman. "Dr. McGlennen brings over 30 years of clinical laboratory leadership, especially when it comes to introducing new technologies into clinical laboratory practice. His contribution will be invaluable to execute the commercialization plan for TELO's multiple myeloma test into clinical practice."
"I am excited to join the Telo Genomics Board of Directors," said Ron McGlennen. "The TeloView® technology is supported by robust evidence and has the potential to provide effective prognostic solutions to critical unmet needs in the management of multiple myeloma and potentially other cancers as well."
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.
For further information, please contact:
Hugh Rogers, Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower,
101 College Street, Suite 200,
Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloViewTM platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
Corporate Logo
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112546
AskMuncher
3年前
$TDSGF Telo Genomics Announces the Outcome of its Participation in the International Myeloma Workshop and Clinical Studies Progress
Press Release | 10/13/2021
Toronto, Ontario--(Newsfile Corp. - October 13, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce updates related to its recent participation in the International Multiple Myeloma Workshop in Vienna, Austria, and progress of the ongoing clinical studies in collaboration with the Mayo Clinic.
TELO has recently participated in the International Myeloma Workshop (IMW 2021) that took place in Vienna, Austria. During the IMW 2021 TELO held important meetings with influential Lead Investigators of multiple myeloma Clinician groups from the USA, France, Spain and Portugal. These meetings were highly productive focused on the development of new collaborations to advance the clinical studies that the Company is currently conducting and in turn accelerate the commercialization of the Company's prognostic tests in-development. TELO also advanced the discussions with potential collaborators addressing additional specific clinical unmet needs in the management of multiple myeloma.
The International Myeloma Society (IMS) is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. IMS promotes the advancement in multiple myeloma disease management through its International Myeloma Workshop (IMW). The IMW is held on an annual basis and includes the meetings of the myeloma guidelines committees. These committees develop, review and revise the guidelines used internationally for multiple myeloma diagnostics and treatments.
The Company also announces that it has successfully completed the processing of the first batch of myeloma samples, which was received from the Mayo Clinic earlier in the year. This batch of patient samples represents the overall feasibility assessment of the ongoing clinical studies included in TELO's collaboration with the Mayo Clinic. During the IMW 2021 TELO held an important meeting with the study's Lead Clinical Investigator from the Mayo Clinic to discuss the results of the Feasibility Assessment samples. TELO is expecting to receive the following batch of samples from the Mayo Clinic within Q4 of the current year.
TELO's collaboration with the Mayo Clinic includes two retrospective clinical studies targeting the development of improved MM prognostic tests: 1) To identify high risk smoldering myeloma patients who will benefit from immediate treatment, and 2) To predict MM patient response to first-line therapy at the point of diagnosis. Each of the 2 studies will be completed in two phases retrospectively with the potential of a third prospective phase.
"Identifying high risk smoldering myeloma patients was the key clinical unmet need highlighted in the IMW 2021," said Sherif Louis, TELO's CEO. "TELO's ongoing clinical studies in collaboration with the Mayo Clinic is focused on addressing this unmet need. The participation in the IMW 2021 was pivotal to introduce the potential of TELO's technology as a disruptive prognostic tool for multiple myeloma to the international myeloma medical community."
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Hugh Rogers, Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
Tina Byers
Investor Relations
Adelaide Capital
Phone: 905.330.3275
E-mail: tina@adcap.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
Corporate Logo
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99483
petunia1
3年前
Telo Genomics Adopts Advanced Notice Provisions in By-Laws
Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announces its board of directors (the "Board") has adopted amendments to its By-Laws (the "Amended By-Laws") to include advance notice provisions (the "Advance Notice Provisions") which require shareholders of the Company ("Shareholders") to provide advance notice to the Company when nominating persons for election to the Board. The Advance Notice Provisions provide the required form and contents for a Shareholder to give notice and fixes the deadline by which Shareholders must submit director nominations to the Company prior to any annual or special meeting of Shareholders.
The Advance Notice Provisions will: (i) facilitate orderly and efficient annual general or special meetings ("AGSM"); (ii) ensure that all Shareholders receive adequate notice of director nominations and sufficient information with respect to all nominees; and (iii) allow Shareholders to register an informed vote.
A shareholder must provide notice (a "Nominating Shareholder") to the Company in proper written form and the notice must be made:
in the case of an annual meeting of Shareholders, not less than 30 nor more than 65 days prior to the date of the annual meeting, provided that
if the Company chooses to use notice and access to deliver meeting materials, the time frame will be not less than 40 and no more than 65 days, and
if the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement of the meeting was made (the "Notice Date"), notice by the Nominating Shareholder may be made not later than the close of business on the 10th day following the Notice Date; and
in the case of a special meeting of Shareholders (which is not also an annual meeting) called for the purpose of electing directors (whether or not called for other purposes), not later than the close of business on the 15th day following the Notice Date.
The Amended By-Laws have been approved by the board of directors, are currently in effect and will be placed before Shareholders for confirmation, approval and ratification at the next AGSM. The full text of the Advance Notice Provisions will be included in the meeting materials sent to the Shareholders for the next AGSM. Pursuant to the Canada Business Corporations Act, if the Amended By-Laws are approved by the Shareholders, the Amended By-Laws will continue to be effective. Failing confirmation by the Shareholders, the Amended By-Laws will cease to be effective.
The Company also previously amended its By-Laws to enable the Company to hold shareholder meetings partially or entirely by telephonic, electronic or other communication facility. This amendment was adopted by the Board and subsequently confirmed by the Shareholders at their annual general meeting held on March 4, 2021.
The Amended By-Laws are subject to the approval of the TSX Venture Exchange.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.
For further information, please contact:
Hugh Rogers, Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
Tina Byers
Investor Relations
Adelaide Capital
Phone: 905.330.3275
E-mail: tina@adcap.ca
petunia1
3年前
Telo Genomics Engages Clinical and Regulatory Affairs Veteran to Lead the Company's ISO 15189 Certification & CLIA Laboratory Accreditation Undertaking
Toronto, Ontario--(Newsfile Corp. - August 9, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that the Company has entered into an agreement with the clinical laboratory veteran Mark Stene, Founder & President of MyClinLab® LLC, Austin, Texas USA. Mark Stene is a former senior executive with several clinical laboratories and medical device enterprises in the USA. Dr. Stene brings a record of accomplishment in guiding biotech companies through the process of achieving clinical laboratory accreditation. Dr. Stene will lead TELO's efforts to achieve the ISO 15189 certification, specific for medical laboratories, and the certified Clinical Laboratory Improvement Amendments (CLIA) accreditation.
"I have previously collaborated with Mark and am excited to have him onboard leading our efforts to achieve laboratory designations for TELO labs," said Guido Baechler, TELO Chairman. "Mark brings over 30 years of executive experience in clinical laboratory management and accreditation; his contribution will be critical in moving the commercialization of our multiple myeloma tests into the clinic in the US and Canada."
Dr. Stene founded MyClinLab in 2019, a Texas based consultancy to provide regulatory and staffing support to biotechnology or service clinical laboratories. Since 1987, Dr. Stene held key positions and executive roles with Veridia Diagnostics, Quest Diagnostics and LabCorp/Esoterix/Endocrine Sciences. In addition to senior administrative responsibilites, he focused on the commercialization of several immunoassay, mass spectrometry and molecular testing methods as clinical laboratory tests. In his career, Dr. Stene has repeatedly led teams transitioning research-based testing into the more regulated clinical laboratory setting. Mark holds a Doctoral Degree in Experimental Pathology and an Executive MBA, both from the University of California, Los Angeles. Dr. Stene is a licensed California Clinical Laboratory Scientist and a licensed New York State Department of Health Laboratory Director.
"I am thrilled to work with the Telo Genomics team," said Mark Stene. "The TeloView® technology is precise, and has the potential to deliver acurate prognostic results to address key clinical unmet needs to identify multiple myeloma patients who will benefit from a specific treatment, predict patient response to treatment, and monitor treatment outcomes over time."
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.
For further information, please contact:
Hugh Rogers, Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
petunia1
3年前
Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma
Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma Patients
Toronto, Ontario, April 29, 2021 – Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”)
is
pleased to announce that it has co-authored a publication demonstrating TELO’s ability to identify high
risk versus low-risk smoldering myeloma patients in a large longitudinal prospective multiple myeloma
clinical study including 214 patients. The study was recently published in the Scientific Journal titled
“Cancers”.
“This study confirms the potential of TeloView® technology to fill an important unmet
diagnostic/prognostic need for multiple myeloma and its precursors,” said Guido Baechler, TELO’s
Chairman. “We see now the potential to accelerate the transition of TeloView® tests towards
commercialization.”
The patient groups included cohorts for the typical stages of the disease, form the least to the most
advanced: monoclonal gammopathy of undetermined significance (MGUS) (n=54); smoldering multiple
myeloma (SMM) (n=24) and multiple myeloma (MM) (n=136). All patient samples were assessed using
Telo Genomics’ proprietary technology platform TeloView®. Patients in the study were followed
prospectively for up to 5 years.
The most important result was the identification of high-risk SMM patients who progressed to active MM
(symptomatic) within 1-3 years from point of diagnosis versuslow risk stable SMM patients who remained
at the smoldering stage (asymptomatic) for over 5 years with high significance. Moreover, TeloView®
analysis identified MM patients with stable form of the disease versus those with aggressive form of the
disease with high significance. Importantly, the quantification of TeloView® parameters correlated with
MM patient’s survival rate. Currently, there is no single clinical test that allows the identification of high
risk versus low risk smoldering myeloma patients.
The results of this study validate the findings of previously published MM clinical studies using TeloView®
that were published in 2014 and 2019, with a total number of 362 patients analyzed to date across the
three published clinical studies.
Multiple myeloma is a highly challenging and deadly blood cancer that forms in plasma cells, a type of
white blood cell. Symptoms include bone pain, frequent infections, fatigue, and weight loss. Smoldering
multiple myeloma is an asymptomatic precursor to active multiple myeloma. There is an increasing
industry trend towards identifying high-risk smoldering multiple myeloma patients to initiate early
treatment and achieve better clinical outcomes (Boutros M. et al 2020). The annual incidence of multiple
myeloma is approximately 32,000 newly diagnosed cases in the USA per year, with approximately 150,000
people currently living with multiple myeloma today.
“This study is pivotal for the progress of the clinical development of TeloView® as a potentially important
prognostic tool for MM patients,” said Dr. Mai, Director and Chair of TELO’s Clinical and Scientific Advisory
Board. “The added value of this study comes from the fact that it is a prospective study with up to 5 years
of follow up data, and included a large cohort of patients.”
The study received funding support to Dr. Sabine Mai from Myeloma Canada and from the Cancer
Research Society.
Reference:
Boutros M. et al Genomic Profiling of Smouldering Multiple Myeloma Identifies Patients at a High Risk of
Disease Progression. J Clin Oncol. 2020 Jul 20;38(21):2380-2389
- 2 -
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7
Tel: 416-673-8487 email: info@telodx.com
https://seer.cancer.gov/statfacts/html/mulmy.html.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the
industry with powerful applications and prognostic solutions. These include liquid biopsies and related
technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant
interest to the medical community for being less invasive and more easily replicated than traditional
diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D
telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic
instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for
patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The
benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications
and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s
disease. Our lead application, Telo-MM is being developed to provide important, actionable information
to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more
information please visit www.telodx.com.
For further information, please contact:
Hugh Rogers, Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
makinezmoney
5年前
$TDSGF: NEWS.... Multiple-Myeloma with Mayo Clinic
Telo Genomics announces Multiple Myeloma collaboration with Mayo Clinic
9:00 AM ET 12/20/19 | GlobeNewswire
Telo Genomics announces Multiple Myeloma collaboration with Mayo Clinic
TORONTO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the "Company" or "TELO"), is pleased to announce that it has signed a collaboration agreement with Mayo Clinic in Minnesota to conduct clinical studies to evaluate and validate the utility of the Company's proprietary telomere analytics as a prognostic solution for Multiple Myeloma.
The collaboration studies will be led by Dr. Shaji Kumar, MD, and were designed to include two retrospective phases with the potential of a third prospective phase. For each phase, TELO's analytics will be employed to: 1) predict the progression of multiple myeloma precursors to full stage multiple myeloma, and 2) predict patient responses to first-line therapy at the point of diagnosis.
Multiple Myeloma ("MM") is a highly challenging blood cancer that forms in plasma cells, a type of white blood cell with an annual incidence rate of approximately 32,000 newly diagnosed cases in North America and approximately 40,000 newly diagnosed cases in Europe. MM is currently incurable but patients may go into remission with treatment. MM is preceded by an asymptomatic expansion of plasma cells, recognized as monoclonal gammopathy of undetermined significance ("MGUS") or smoldering MM ("SMM"). Patients with MGUS or SMM are generally not treated but monitored regularly to capture the onset of full stage MM if the patient progresses. Once patients are diagnosed with full stage MM they may be treated with several available treatment regimens; however, it is estimated that 20% of the patients will relapse on first line treatment within 12-15 months. Predicting patient progression from MGUS or SMM to full stage myeloma, and predicting patient response to first line therapy remain critical unmet needs in the clinic.
"Telo Genomics technology has shown promising results in several academic studies focused on blood cancers including Multiple Myeloma," commented Dr. Kenneth Anderson, Dana-Farber Cancer Institute, and member of TELO's Clinical and Scientific Advisory Board.
Phase 1 of the studies is expected to be launched within the first quarter of 2020.
"We are excited to work with Dr. Kumar," said Sherif Louis, CEO of Telo Genomics. "TELO's board of directors has identified Multiple Myeloma as a priority initiative for the Company's clinical programs, these studies are foundational to advance TELO-MM tests towards commercialization."
About Telo Genomics
Telo Genomics (TELO) is a world leader in the quantitative analysis of telomeres, with a particular focus on liquid biopsy diagnostics and prognostics. Its proprietary platform technology has the potential to be a powerful healthcare tool to improve the diagnosis and treatment of several cancers and neurological diseases. TELO employs a proprietary software platform, TeloView(R) , to precisely quantify specific features of patient's telomeres in three dimensions. This technology has been successful in detecting early disease, determining the aggressiveness and progression of disease and providing powerful insights to guide therapy and treatment protocols, all of which should contribute to improved clinical outcomes for patients. TELO benefits from over 20 years of foundational and translational academic research conducted by the Company's founder providing a wealth of more than 150 peer reviewed publications, 25 clinical studies involving more than 3,000 patients and 20 different cancers and Alzheimer's disease.
For further information, please contact:
Hugh Rogers
Chairman
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the consolidation, the offering, the use of proceeds are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
> Dow Jones Newswires
December 20, 2019 09:00 ET (14:00 GMT)
petunia1
7年前
3D Signatures Announces Intention to File for Bankruptcy
TORONTO, May 31, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM) based on the three-dimensional analysis of chromosomal signatures, today announced its intention to assign itself into bankruptcy under the Bankruptcy and Insolvency Act (the “BIA”) and the layoff of its employees and contractors.
As a research and development stage company, 3DS is primarily dependent on funding from investors to continue as a going concern. While 3DS has been successful in reducing its overall cost structure, it has been unable to secure the additional financing required to fund its operations. As a result, the Company intends to assign itself into bankruptcy under the BIA. In addition, the Company has conducted a layoff of its employees and contractors. Subsequent to the filing of the assignment into bankruptcy, the Licensed Insolvency Trustee may request certain key employees to provide assistance with its administration. The Board of Directors of 3DS has not resigned and will cooperate fully with the Licensed Insolvency Trustee once they are retained in accordance with the resolution passed by the Board of Directors on May 30, 2018.
Third Quarter Financial Summary
The Company significantly reduced its cash monthly burn rate and recorded a net loss of $920,758 ($0.01 per Common Share) for the three months ended March 31, 2018 compared to $2,171,822 ($0.04 per Common Share) for the three months ended March 31, 2017.
As at March 31, 2018, the Company had cash resources of $618,411 compared to $1,200,395 as at June 30, 2017 and $2,552,822 at March 31, 2017. As at March 31, 2018 the Company had working capital of $390,689 compared to working capital of $1,329,408 as at June 30, 2017 and $3,215,197 at March 31, 2017.
The Company’s financial statements and management’s discussion and analysis are available on www.sedar.com.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform, TeloView™, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloView™ software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloView ScoreTM.
For more information, visit the Company’s website at: http://www.3dsignatures.com.
For further information, please contact:
Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements which constitute “forward-looking information” within the meaning of applicable Canadian securities legislation (“Forward Looking Statements”). All statements included herein, other than statements of historical fact, are Forward-Looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward-Looking Statements. Often, but not always, these Forward-Looking Statements can be identified by the use of words such as “intends”, “expects” "estimates", "potential", "open", "future", "assumes", "projects", “anticipates”, “believes”, “may”, “continues”, "plans", "will", "to be", or statements that events "could" or "should" occur or be achieved, and similar expressions, including negative variations. Statements with respect to 3DS’ intention to file an assignment under the BIA, the expectation that the CEO and CFO will continue with the Company to assist with the bankruptcy proceedings, among others, are Forward-Looking statements.
Such Forward-Looking Statements reflect the Company’s current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by 3DS as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many risk factors could cause the Company’s actual results, performance, achievements, prospects or opportunities to be materially different from any future results, performance or achievements that may be expressed or implied by such Forward-Looking Statements, including risks related to the filing of an assignment under the BIA by the Company, the expectation that the CEO and CFO will continue with the Company to assist with the bankruptcy proceedings, and the timing of the bankruptcy proceedings, as well as those risks discussed under the heading "Risk Factors" in the Company's annual management’s discussion and analysis dated October 23, 2017 and filed on SEDAR. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the Forward-Looking Statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.
In making the Forward-Looking Statements, the Company has made various material assumptions including, but not limited to, 3DS’ ability to complete the assignment under the BIA in a timely and orderly fashion.
3DS believes that the assumptions and expectations reflected in the Forward-Looking Statements in this press release are reasonable, but no assurance can be given that these expectations will prove to be correct. Forward-Looking Statements should not be unduly relied upon. This information speaks only as of the date of this press release, and 3DS will not necessarily update this information, unless required to do so by securities laws.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
petunia1
7年前
3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL(TM) Test for Hodgkin ’s Lymphoma
TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM) based on the three-dimensional analysis of chromosomal signatures, is pleased to announce the successful and on-time development of the scoring model for Telo-HLTM, the Company’s lead test for Hodgkin’s lymphoma (“HL”), as well as completion of an analytical validation study to confirm the reproducibility of its Telo-HLTM test.
Powered by the Company’s proprietary TeloViewTM platform, Telo-HLTM is a predictive test performed on diagnostic lymph node biopsy specimens, intended to provide clinicians with the first biomarker capable of identifying the 15% - 20% of HL patients who will fail standard ABVD chemotherapy, and who should immediately be considered for more advanced treatment or inclusion into clinical trials with an emerging immunotherapy.
The study data from the Company’s multi-parametric telomeric analysis with TeloViewTM was analyzed by an independent statistical provider, BioStat Solutions Inc. (“BSSI”), to develop the Telo-HLTM scoring model from over 200 potential predictors that included different combinations of the telomeric nuclear organization, cell type, and clinical parameters. BSSI identified that a combination of at least three of the parameters analyzed by TeloViewTM contributed to the scoring model with highly predictive characteristics. This included measures unique to 3DS’s platform, which can only be evaluated through three-dimensional analysis of telomeres, and for which current clinical data alone is insufficient to predict risk of relapse.
In addition, the Company reports it has successfully run an internal analytical validation of the test by processing and analyzing, in triplicate, archived samples from the same patients. This important step demonstrates the consistency of the Telo-HLTM test and reproducibility of TeloViewTM results under a variety of conditions.
“In keeping with best practices, external scientific peer-review is now essential to confirm our own evaluation of Telo-HLTM’s strong performance and reproducibility,” notes Dr. Kevin Little, CSO of 3DS. “The detailed findings will be submitted as quickly as possible for presentation in clinician meetings, and then publication in a top-level clinical journal in the latter half of 2018. This will build awareness with key opinion leaders and pharmaceutical companies that Telo-HLTM is ready and available to be incorporated into clinical trials as a correlative biomarker alongside new therapeutic interventions.”
“This is the most significant accomplishment for the Company yet, and I congratulate everyone involved for achieving this critical milestone as per our plan,” commented Jason Flowerday, CEO of 3DS. “This highly successful study is an important culmination of the work by Dr. Sabine Mai and the 3DS team, to develop the first clinically-compliant and validated test based on telomeric profiling, which can uniquely inform treatment decisions in Hodgkin’s lymphoma. Telo-HLTM represents a critical proof-of-principle for the Company’s TeloViewTM platform that we believe may establish an entirely new clinical paradigm for genome organization, and accelerate the development of our broader platform of TeloViewTM-based tests in prostate cancer, lung cancer and multiple myeloma.”
About 3DS
3DS (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform, TeloView™, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloView™ software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloView ScoreTM. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.
The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer’s disease.
For more information, visit the Company’s website at: http://www.3dsignatures.com.
For further information, please contact:
Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com
Bassman101
7年前
3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer
TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM) based on the three-dimensional analysis of chromosomal signatures, is pleased to announce that it has signed a collaboration agreement with MDxHealth SA (Euronext: Brussels MDXH.BR) (“MDxHealth”), a world leader in molecular diagnostics for urological cancers, to evaluate 3DS’ prognostic test candidate for prostate cancer (“Telo-PCTM”), using 3DS’ proprietary TeloView™ software platform.
3DS and MDxHealth will share the costs of conducting the collaborative study. Pursuant to the agreement, 3DS has also granted MDxHealth an exclusive option to negotiate a license agreement for the Telo-PCTM test.
“This is an excellent opportunity, combining our expertise in urological diagnostics with the innovative 3DS software platform, to evaluate an exciting technology that may improve the clinical management of patients with prostate cancer,” said Dr. Jan Groen, CEO of MDxHealth. “MDxHealth is constantly evaluating new opportunities that might allow us to increase our commercial footprint and we look forward to collaborating with 3DS to explore the potential of this partnership.”
There is a significant unmet need for accurate and minimally invasive diagnostic and risk-assessment tools that allow clinicians to make more informed treatment decisions for prostate cancer patients. Traditionally, the diagnosis of prostate cancer has involved repeated invasive tissue biopsies, which can easily miss cancerous cells or misinterpret benign conditions as being dangerous, leading to unnecessary surgeries. This system needs urgent improvement as seen by the sheer number of people across the world affected by prostate cancer. According to the World Health Organization1, there were over 570,000 new cases of prostate cancer in the U.S. and Europe in 2012. The U.S. National Institutes of Health2 estimates there were over 3 million men living with prostate cancer in the United States in 2014. Currently, prostate cancer patients are often faced with the difficult choice of either living with the cancer under active surveillance, or pursuing treatment which has a significant risk of devastating side effects such as erectile dysfunction, incontinence, bowel complications and infection.
“We look forward to expanding the evaluation of our TeloViewTM platform in prostate cancer through a collaboration with MDxHealth, as they are recognized world leaders in molecular diagnostic testing for patients with prostate cancer,” commented Jason Flowerday, CEO of 3DS. “We hope this study will continue to build on the evidence observed to date which indicates that our Telo-PCTM test is able to predict the stability and aggressiveness of prostate cancer through three-dimensional nuclear telomeric profile analysis.”
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of urological cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform, TeloView™, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloView™ software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloView ScoreTM. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.
The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.
For more information, visit the Company’s website at: http://www.3dsignatures.com.
The information concerning MDxHealth contained in this news release has been provided by MDxHealth. Although 3DS has no knowledge that would indicate that any statements contained herein concerning MDxHealth are untrue and incomplete, the directors and officers of 3DS assume no responsibility for the accuracy and completeness for such information.
For further information, please contact:
Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com
http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp
https://seer.cancer.gov/statfacts/html/prost.html
Bassman101
7年前
3D Signatures Inc. and l ’Institut Universitaire de Cardiologie et de Pneumologie de Qu ©bec (IUCPQ) Announce Collaboration to Combine TeloView ™ with Genome Sequence Analysis in Lung Cancer
TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, is pleased to announce that it has signed a collaboration agreement with l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (“IUCPQ”) to evaluate the clinical application of 3DS’ proprietary TeloView™ software platform alongside DNA sequence analysis in lung cancer.
The study will be conducted at 3DS’ laboratory in Toronto, Canada, through a collaboration with Dr. Philippe Joubert (MD, PhD, FRCPC), anatomic pathologist at the IUCPQ, researcher at the IUCPQ Research Center, and assistant clinical professor in the Department of Molecular Biology, Medical Biochemistry, and Pathology at Laval University. IUCPQ will conduct whole exome sequence analysis, and provide 3DS with matching tissue samples from the IUCPQ Tumor Bank, from patients with non-small cell lung cancer (NSCLC).
“Pathologists have a variety of emerging technologies available that may offer new insights into optimal disease management”, states Dr. Joubert. “This pilot is an exciting opportunity to evaluate how three-dimensional telomere analysis may complement other new tools at our disposal to offer potential benefits to healthcare providers, lung cancer patients, and the healthcare system”.
According to the World Health Organization, lung cancer is the most common cancer in the world, accounting for over 1.8 million new cases annually, and remains the leading cause of cancer deaths each year.1 Targeted therapies against specific gene mutations have had an important but limited effect on the total lung cancer population. The recent introduction of immunotherapies has been highly effective in only a minority of patients because clinicians lack robust biomarkers to predict which patients will benefit from these expensive treatments.
“We look forward to this additional collaboration with Dr. Joubert and the IUCPQ, to further expand TeloView’s potential application as a universal clinical biomarker in cancer,” commented Jason Flowerday, CEO of 3DS. “We hope this pilot study will be an important precedent for demonstrating how our TeloView™ platform may integrate with genomic sequencing with the aim of supporting clinical decisions for the precision care of such a large patient population as lung cancer.”
About the IUCPQ
Since its creation in 1918, the Institut Universitaire De Cardiologie et de Pneumologie de Quebec has stood on equal footing with leading North American establishments for ultra-specialized care. Specializing in the health of persons with cardiopulmonary diseases, the Institute is renowned and recognized internationally as a leader. What distinguishes the Institute is its expertise and innovative practices, its focus on research and teaching, and its technological advances. The Institute is where specialized expertise and the sharing of knowledge come together in an ongoing quest for excellence. The close and continuing synergy between clinical activities, research, teaching and the evaluation of health technologies and interventions ensures a care approach guided by best practices and forms the cornerstone of the Institute's mission.
About the IUCPQ Research Center
The Québec Heart and Lung Institute (IUCPQ) Research Centre is the only centre funded by the Fonds de recherche du Québec – Santé (FRQS) that regroups three research components (cardiology, respirology and obesity-metabolism) deemed to be a priority because of the considerable economic and social impact of their related diseases. Our centre is unique in that our research components perfectly complement the Institute’s clinical missions. This enables health professionals and researchers to work in total synergy to the greatest benefit of patients. Since 2000, the personnel went from 268 to 906 employees, including 171 principal investigators.
For more information, visit the Institute’s website: http://iucpq.qc.ca/en
The information concerning IUCPQ contained in this news release has been provided by IUCPQ. Although 3DS has no knowledge that would indicate that any statements contained herein concerning IUCPQ are untrue and incomplete, the directors and officers of 3DS assume no responsibility for the accuracy and completeness for such information.
About 3DS
3DS (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform, TeloView™, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloView™ software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloView™ platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloView Score™. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloView™ platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.
The TeloView™ platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.
For more information, visit the Company’s website at: http://www.3dsignatures.com.
For further information, please contact:
Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com
Bassman101
7年前
EXCITING BIOTECH STOCK NOW BREAKING OUT OF LARGE BASE...
Originally published Sunday, March 04, 2018
3D Signatures is an exciting Biotech company that now appears to be getting its act together fast, which is reflected in the recent action in its stock, although it is certainly not too late to buy the stock, otherwise we wouldn’t be interested in it. With respect to the fundamentals it is liked here by AlphaNorth Capital’s Steve Palmer for the reasons stated briefly in his recent article looking at 3 Small Caps that he favors.
We’ll now see what the charts have to say about it. On an 18-month log chart we can see all of the action in the stock since its inception, and the log chart has the advantage that it opens out the recent base pattern that has just completed, so that we can examine clearly what has been going on. As we can see, the severe decline through most of last year led into a fine large Head-and-Shoulders bottom formation that it started to break out of only a week ago. It didn’t hold a clear breakout and has dipped back to support at the upper boundary of the base pattern. This of course was partly due to the broad stockmarket diving, but as far as its chart is concerned it was due to a still challenging moving average alignment – we have yet to see a cross of the moving averages and the 200-day is still falling steeply – basically it needs a little more time, which is why it reacted back. Additional bullish points to observe on this chart are the high volume on the breakout move – the highest for about 10 months – which is bullish, the now climbing Accum-Distrib line, also positive and the improving momentum which has swung from negative to positive.
https://www.clivemaund.com/charts/dxd18month040318.jpg
The 3-month chart is valuable here as it enables us to see recent action in much more detail. Observe first the heavy volume when it broke out of the Head-and-Shoulders bottom about a week ago, which is bullish, and it is thanks to the broad market drop and still challenging moving average alignment, as mentioned above, that it has dropped back to what is considered to be a good entry point, given that we missed the opportunity to buy it near to the Right Shoulder low of the H&S pattern. Two factors that we can see to advantage on this chart which strongly suggest that it will turn higher from here are that it has reacted back to support at the January highs and the upper boundary of the entire base pattern, and also that volume has shrunk back to a very low level as it has reacted back, suggesting that there are few sellers at lower prices, because holders do not want to sell, for good reason. It could react back a little further but it is considered more likely that it will advance from here.
https://www.clivemaund.com/charts/dxd3month040318.jpg
Conclusion: 3D Signatures is viewed as a strong buy here for a resumption of its advance to complete its breakout from its large Head-and-Shoulders bottom pattern, which should usher in a major bullmarekt advance in this stock. The company’s stock trades in rather light volumes on the US OTC market, which are expected to improve as it advances.
3D Signatures website
3D Signatures Inc, DXD.V, TDSGF on OTC, closed at C$0.33, $0.252 on 2nd March 18.
Bassman101
7年前
3D Signatures Reports Quarter Ended December 31, 2017 Financial Results
TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, today reported operational and financial results for its fiscal second quarter ended December 31, 2017. 3DS also announced that it has terminated its investor relations services agreement with Terry Bramhall of Clearcut communications.
Second Quarter Operational Highlights
The primary operational milestones achieved in the Company’s second financial quarter of 2018 include completion of the clinical study component of its Telo-HLTM validation program, announced October 10, 2017, as well as two non-brokered private placements totaling $2,622,673, announced October 4th and December 5th, 2017. 3DS also announced on October 10, 2017, that two new patents governing high-resolution imaging in cancer progression and the stratification of Alzheimer’s patients had been issued by the United States Patent and Trademark Office.
Telo-HLTM is intended to provide clinicians with the first biomarker to identify the 15% - 20% of new Hodgkin’s lymphoma patients who will likely fail standard chemotherapy, and who should immediately be considered for more advanced treatment or inclusion into clinical trials to access emerging treatments such as immunotherapies. The Company believes that Telo-HLTM could provide several advantages to patients and healthcare system payers, including potentially indicating new treatment options, enabling shortened treatment cycles, reducing complications from ineffective treatments and allowing for treatment cost savings.
Subsequent to the end of the quarter, on February 20, 2018, the Company announced positive topline results from its Telo-HLTM study. Preliminary third-party analysis of the study data for Telo-HLTM shows that the Company’s TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
Six Month Financial Summary
Through efforts that are still ongoing, the Company significantly reduced its monthly burn rate and recorded a net loss of $2,621,655 ($0.05 per Common Share) for the six months ended December 31, 2017 compared to $4,976,684 ($0.13 per Common Share) for the six months ended December 31, 2016.
As at December 31, 2017, the Company had cash resources of $1,422,134 compared to $1,200,395 as at June 30, 2017. As at December 31, 2017 the Company had working capital of $1,016,957 compared to working capital of $1,329,408 as at June 30, 2017.
The Company’s financial statements and management’s discussion and analysis are available on www.sedar.com.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform, TeloView™, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloView™ software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloView ScoreTM. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.
The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.
For more information, visit the Company’s website at: http://www.3dsignatures.com.
For further information, please contact:
Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com
Bassman101
7年前
Can a Simple Test Really Predict Whether a Cancer Treatment Will Succeed?
Source: Streetwise Reports (2/20/18)
http://bit.ly/2BDIbBs
Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma.
Teloview
Doctors know that for people with Hodgkin's lymphoma, the standard treatment—ABVD chemotherapy—will fail in roughly 15-20% of patients.
But the trick is knowing which 15 or 20 people out of 100 fall into that group.
Having that knowledge would save patients from going through debilitating and costly chemotherapy treatments, only to relapse. It would allow oncologists to treat those patients initially with targeted therapy that's appropriate for them before their bodies are weakened by unsuccessful first-line chemotherapy.
Such a test for Hodgkin's lymphoma is being developed by Toronto-based 3D Signatures Inc. (DXD:TSX.V; TDSGF:OTCQB; 3D0:FSE).
Telomeres, located at the tips of each chromosome, are protective regions of DNA. 3D Signatures notes that the "3D organization of telomeres within a given cell is highly predictive of the disease status of the patient."
Using the company's TeloViewTM platform, which is a proprietary biomarker-based approach to personalized medicine, the Telo-HLTM test for Hodgkin's Lymphoma has been in trials.
"I like the fact that 3DS has a platform technology. It has applications for various diseases and medical conditions." – Steve Palmer, AlphaNorth Asset Management
3D Signatures has just announced that preliminary analysis of trial data for Telo-HLTM confirms what was seen in previous small-scale studies, and shows the "TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months."
Using specimens from more than 400 Hodgkin's patients in Canada and Europe, who were treated with ABVD, the three-part process included "a wet lab co-immuno-telomeres FISH assay, 3-dimensional imaging (with identification of 30 Hodgkin and 30 Reed-Sternberg cells), followed by TeloView™ software analysis."
3D Signatures shared the results with its statistical partner BioStat Solutions Inc., which "compared the TeloViewTM data with the corresponding clinical outcomes for patients, and identified highly significant group differences across multiple TeloViewTM parameters."
Ronald Bromley, CEO of BSSI, stated,"BSSI is excited to be collaborating with 3DS, helping them ensure the quality of the data being used is to the highest standards, and that they are poised to deliver the best possible analysis of this predictive technology for HL treatment."
Jason Flowerday, CEO of 3D Signatures, noted, "We believe that these results from the application of our TeloViewTM platform to Hodgkin's lymphoma are so strong, the Company will now even more confidently proceed with developing the final scoring model for its Telo-HLTM test to predict response at the individual patient level."
"This is great news for the Telo-HLTM program, and we remain on track to complete all phases of the test development and analytical validation by April 2018," Flowerday added.
"I expect 3DS' shares to advance in lockstep with the company's development of their telomere technology." – Daniel Carlson, Tailwinds Research Group
According to the National Institutes of Health, there are more than 200,000 patients living with Hodgkin's lymphoma in the U.S.; an estimated 200,000 new cases arise each year globally, of which 30,000 are in North America and the European Union. The medical cost for a relapsing patient in the U.S. is approximately $400,000, compared to $90,000 for a non-relapsing patient.
The company also announced that it intends to submit the pending final results from this Telo-HLTM development trial to a highly reputable clinical journal for peer-review and publication in the second half of 2018.
3D Signatures is also developing similar tests on its TeloViewTM platform for a number of much more prevalent cancers, including prostate cancer, lung cancer and multiple myeloma as well as possible diagnostic test for Alzheimer's Disease.
3D Signatures is on the investment radar of AlphaNorth Asset Management. Steve Palmer, AlphaNorth's chief investment officer, told Streetwise Reports, "One of the key things I look for in an investment is a company that has something that is proprietary and a strong growth profile."
On 3D Signatures, Palmer said, the company "has a platform technology that analyzes a component of a person's DNA called telomeres and then is potentially able to predict the outcome of various medical treatments. I like the fact that it's a platform technology. It has applications for a wide variety of diseases and medical conditions. Also, the timeline to have a commercial product is much shorter and lower risk than a traditional biotech company developing a new drug."
Daniel Carlson of Tailwinds Research Group noted on Jan. 5 that "3DS is poised to enter into several partnerships for its interesting technology. Meanwhile, the stock's valuation discounts all success. I expect shares to advance in lockstep with the company's development of their telomere technology and for 2018 to mark a dramatic turnaround for the Company."
Read what other experts are saying about:
3D Signatures Inc.
Want to read more about Life Sciences Tools & Diagnostics? Sign up to receive the FREE Streetwise Reports' newsletter.
Newsletter Sign-Up
your email address
SUBSCRIBE
Disclosure: Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: 3D Signatures. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of 3D Signatures, a company mentioned in this article.
Additional Disclosures
For a list of disclaimers and disclosures for Tailwind Research Group, please click here.
Funds controlled by AlphaNorth Asset Management hold shares of 3D Signatures
petunia1
7年前
3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL ™ Test for Hodgkin ’s Lymphoma
TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HLTM, 3DS’ test in development for Hodgkin’s lymphoma (HL), shows that the Company’s TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.
Telo-HLTM is intended to provide clinicians with the first biomarker to identify the 15% - 20% of new HL patients who will likely fail standard chemotherapy, and who should immediately be considered for more advanced treatment or inclusion into clinical trials to access emerging treatments such as immunotherapies.
3DS has established a clinically-compliant methodology for application of its TeloViewTM process to diagnostic Hodgkin lymphoma biopsy samples, employing more sensitive imaging technology than its previous HL trials. Specimens from over 400 HL patients (who were subsequently treated with ABVD) were processed for this trial, from four contributing hospital sites across Canada and Europe. The 3DS three-step process was applied, comprising a wet lab co-immuno-telomeres FISH assay, 3-dimensional imaging (with identification of 30 Hodgkin and 30 Reed-Sternberg cells), followed by TeloView™ software analysis.
The multi-parametric telomeric analysis with TeloViewTM was performed by 3DS (blinded to patient status), and the results were then shared with statistical partner BioStat Solutions Inc. (“BSSI”), who compared the TeloViewTM data with the corresponding clinical outcomes for patients, and identified highly significant group differences across multiple TeloViewTM parameters.
"BSSI is excited to be collaborating with 3DS, helping them ensure the quality of the data being used is to the highest standards, and that they are poised to deliver the best possible analysis of this predictive technology for HL treatment,” said Ronald L. Bromley, CEO of BioStat Solutions, Inc.
“We believe that these results from the application of our TeloViewTM platform to Hodgkin’s lymphoma are so strong, the Company will now even more confidently proceed with developing the final scoring model for its Telo-HLTM test to predict response at the individual patient level,” said Jason Flowerday, CEO of 3D Signatures. “This is great news for the Telo-HLTM program, and we remain on track to complete all phases of the test development and analytical validation by April 2018.”
The Company intends to submit the completed test development and validation work to a highly reputable clinical journal for publication in the latter half of 2018.
“This trial builds on the foundational work done in Dr. Sabine Mai’s academic laboratory to establish 3D telomere profiling as a novel biomarker platform. We see this as a new genomic stability testing paradigm applicable broadly across clinical trial research and laboratory medicine”, says Dr. Kevin Little, CSO of 3D Signatures.
About Telo-HL™
Powered by 3DS’ proprietary TeloView™ software platform, Telo-HL™ is intended to provide clinicians with the first set of biomarkers that will distinguish between patients that will respond to standard ABVD chemotherapy, and the 15% - 20% of patients who will fail standard chemotherapy and be refractory or relapse within the first year. The Company expects Telo-HL™ to benefit patients seeking personalized treatment and to provide significant cost savings to payors and insurers that are currently burdened with expensive treatments and procedures that may not be necessary if patients could be considered for more targeted and effective therapies at the outset of treatment.
About BSSI
BioStat Solutions, Inc. (BSSI) is a privately held professional service corporation providing statistical and bioinformatics expertise to pharmaceutical and biotech companies as well as to the government and its contractors. BSSI’s diverse team of statisticians, bioinformaticists, epidemiologists and geneticists provides answers to complex and challenging analytical questions. Whether the client is facing big data or machine learning problems, or is looking for new biomarker or diagnostic device strategies, BSSI provides solid results towards effective decision-making. For more information, visit BSSI’s website at: http://www.biostatsolutions.com.
About 3DS
3DS (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform, TeloViewTM, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloViewTM software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloView ScoreTM. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.
The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.
For more information, visit the Company’s website at: http://www.3dsignatures.com.
For further information, please contact:
Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com
petunia1
7年前
Streetwise Reports Features 3D Signatures
Test for Personalized Approach to Hodgkin's Lymphoma
Treatment Entering Final Stages Before Commercialization
Source: Streetwise Reports (1/16/18)
One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company,
which is at the forefront of using three-dimensional telomere analysis to personalize
medical treatment.
3D Signatures Inc. (DXD:TSX.V; TDSGF:OTCQB; 3D0:FSE) has developed a propriety software platform, TeloView, that conducts 3D analysis of chromosomal signatures. "Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity," the company has noted. The analytics can tell "doctors how to personalize treatment and best manage the disease for each individual patient."
The firm completed a Stage 3 clinical trial component for its Hodgkin's lymphoma test, Telo-HLTM, in October; the test is powered by their proprietary TeloViewTM software platform. The aim of the Telo- HLTM test is to divide patients at the point of diagnosis into those who will respond to standard chemotherapy and those who will not, and should be considered for a more targeted, and expensive, second-line therapy.
Currently, patients for whom the standard chemotherapy treatment fails then have to go on to a number of additional interventions and more aggressive alternative treatments. Patients with a relapsing form of the disease often are weakened by the initial chemo treatments so they do not respond as well to the subsequent treatment.
While about 80% of Hodgkin's patients respond to the standard chemotherapy regimen, 3D Signatures CEO Jason Flowerday told Streetwise Reports that the goal of the test is to identify the 20% of patients who will relapse and require additional therapies, to save them from treatments that are unlikely to succeed. In addition, the company believes that its Telo-HLTM test could "provide significant cost savings to payors and insurers that
are currently burdened with expensive treatments and procedures that may not be necessary if patients could be considered for more targeted and effective therapies at the outset of treatment."
3D Signatures is now having the Telo-HLTM data validated by a third-party statistical provider, as well as preparing for validation of the scoring model. If both validations are successful, the company plans to make the
test commercially available in the coming months. In addition to the Hodgkin's lymphoma test, 3D Signatures is developing diagnostic and prognostic products
for prostate cancer, multiple myeloma and lung cancer, all at various stages of development, and finally for Alzheimer's disease, a diagnostic test that has successfully completed two blinded research studies.
On Jan. 5, Daniel Carlson of Tailwinds Research Group noted that for 3D Signatures, "2017 was a year to forget. The stock went down dramatically on the back of a very poor financing effort. However, like the Phoenix, sometimes big disasters can turn into outstanding revivals. 3DS is poised to enter into several
partnerships for its interesting technology. Meanwhile, the stock's valuation discounts all success. I expect shares to advance in lockstep with the company's development of their telomere technology and for 2018 to mark a dramatic turnaround for the Company."
3D Signatures has approximately 63 million shares outstanding with about 27% controlled by insiders. The company's market cap is approximately CA$18 million.
Read more at http://www.stockhouse.com/companies/bullboard/v.dxd?postid=27376865#6fxIb8l3cQ0ZhOcq.99
petunia1
7年前
3D Signatures Inc. Announces the Closing of its Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce that its previously disclosed non-brokered private placement (the “Private Placement”) has been fully subscribed for and has closed for aggregate gross proceeds to 3DS of $1,622,673.
The Private Placement involved the sale of 8,113,365 units (the “Units”) at a price of $0.20 per Unit. Each Unit consists of one common share of the Company and one common share purchase warrant exercisable at $0.35 until December 5, 2022. All securities issued pursuant to the Private Placement are subject to a four month hold period in accordance with applicable Canadian securities laws.
In connection with the Private Placement, the Company paid certain finders a cash commission totalling $91,704, equal to 6% of the gross proceeds raised under the Private Placement by these finders, and issued such finders a total of 458,520 non-transferrable warrants (each, a “Finder’s Warrant”), equal to 6% of the number of Units issued by the Company to investors introduced to the Company by these finders. Each Finder’s Warrant is exercisable to purchase one common share until December 5, 2019 at an exercise price of $0.35.
The Company intends to use the net proceeds from the Private Placement to fund clinical trials, and for working capital and general corporate purposes. The Company expects that approximately $750,000 of the Private Placement will be used to fund clinical expenses, including the Company’s test for Hodgkin’s lymphoma, Telo-HL™, which requires validation of the scoring model as well as analytical validation prior to expected commercial launch as a laboratory developed test (“LDT”) in the first quarter of 2018. The balance of the Private Placement is expected to be used to fund general working capital expenses.
"We greatly appreciate the confidence shown in 3DS by the investors who participated in this financing,” commented Jason Flowerday, CEO of 3DS. “This financing has provided us with resources to continue implementing our strategic plan, which includes the anticipated commercial launch of our Hodgkin’s lymphoma test as an LDT in Q1 2018.”
Certain insiders of the Company participated in the Private Placement by purchasing an aggregate of 230,000 Units. Accordingly, the Private Placement constitutes, to that extent, a "related party transaction" under applicable Canadian securities laws. The Company is relying on the exemptions from the formal valuation and minority approval requirements found in sections 5.5(a) and section 5.7(1)(a) of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Company’s market capitalization. The Company did not file a material change report more than 21 days before the expected closing of the Private Placement as the details of the Private Placement and the participation therein by related parties of the Company were not settled until shortly prior to closing and the Company wished to close on an expedited basis for sound business reasons.
This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.
About 3DS
3DS (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s website at: http://www.3dsignatures.com.
For further information, please contact:
Jason Flowerday
CEO & Director
604-428-8842
investors@3dsignatures.com
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
OptimusPrime555
4年前
TrendTrade2016
4年前
Renee
5年前
